Plain-English translation of NCT06487546 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Dialysis is a life-saving treatment that removes harmful waste from the blood when kidneys fail. But it also removes some potentially helpful nutrients, including a chemical called ergothioneine that normally comes from food. This study tests whether taking ergothioneine as a daily supplement can safely restore healthy levels of this nutrient in people receiving dialysis.
People on dialysis have low levels of this nutrient in their blood, and researchers believe restoring it might help protect their health. This trial will determine whether the medication can effectively rebuild these nutrient levels.
You likely qualify if…
You likely don't qualify if…
You will take either the ergothioneine supplement or a placebo (a matching pill with no active ingredient) once daily by mouth for up to 12 weeks. Half of the participants will receive the actual supplement, and half will receive placebo, assigned randomly. The research team will monitor your blood levels to see how well the treatment works.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Enrollment target
~28 participants
Started
April 2025
Primary completion
April 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tammy Sirich, MD
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.